R&D Day: Updates on the Development of the Company’s Ovarian Cancer and Endometriosis Tests:
Date: January 4, 2024
Time: 11:00 AM ET
Location: Virtual
Replay: https://lifescievents.com/events/aspirawomenshealth/

The call will be hosted by Nicole Sandford, President and CEO. She will be joined by Jody Berry, PhD, Chief Scientific Officer for Aspira Women’s Health, and Kevin Elias, MD, Assistant Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School, Director of Gynecologic Oncology Laboratory at Brigham and Women's Hospital in Boston, Massachusetts, gynecologic oncologist, and surgeon-scientist at Dana-Farber Cancer Institute.

After a brief overview of the current treatment pathway for ovarian cancer and endometriosis, our panelists will provide an update on each of the company’s in-development products, including how each can close clinical gaps and improve health outcomes for women. Product updates will include upcoming milestones, pending publications, and future revenue potential for:

OvaWatchSM
The only commercially available ovarian cancer blood test for women diagnosed with an adnexal mass considered indeterminate or benign by initial clinical assessment. It will soon be available for longitudinal mass monitoring.

OvaMDx™
A promising new blood test that combines Aspira’s proprietary protein biomarker technology with miRNAs licensed from the Dana Farber Cancer Institute.

EndoCheckSM
The first protein biomarker test for the identification of ovarian endometriosis, including endometrioma.

EndoMDx™
A multimarker test that combines proteins, miRNA, and clinical data for the identification of endometriosis developed in collaboration with a consortium of academic and clinical partners led by the Dana Farber Cancer Institute.

A live question and answer session will follow the formal presentations.